INTI Developed a Key Standard for the Cannabis Industry

INTI specialists developed a standard (certified reference material) of THCA, a non-psychoactive component present in stems, leaves and flowers of the cannabis plant. It is believed to have multiple health benefits, such as anti-inflammatory and neuroprotective properties.

This launch will not only make it possible to replace imports, reduce time and costs, but it is also essential to improve the precision and quality of measurements in the country, thus guaranteeing effective quality control.

The process of obtaining these materials complies with ISO 17034:2016, from the transfer of the plant material by a producer linked to INTI to the stage of extraction, purification and determination of its identity, purity and uncertainty using high-precision methods.

Read more about the key standard developed by INTi and read the latest cannabis news of the day with the Hemp.im mobile app

INTI plays an important role in the cannabis industry in Argentina

Once prepared, the material is tested to ensure its uniformity and stability before being released and delivered with a certificate and its respective safety data sheet.

In a context of global growth of the cannabis industry and legislative developments in Argentina, INTI plays a key role in the quality control of cannabis-derived products by developing standards to measure their active components.

As a background, in 2022, INTI delivered the first pilot batch of tetrahydrocannabinol (THC) to public laboratories of the CONICET’s Network of Cannabis for Medical and Industrial Use (RACME) and in the current year it donated 48 units of cannabidiol (CBD) to these laboratories.

The dissemination of these pilot batches has made it possible to evaluate the results of the measurements, the different methods used and has opened the door for the future harmonization of working methods in this emerging industry. These actions lay the groundwork for establishing quality criteria for measurements.

INTI is currently organizing the first cannabinoid interlaboratory test through the Argentine Interlaboratory Service (SAI) to ensure the technical competence of these facilities and improve the quality of cannabis measurements at the national level.

__

(Featured image by Washaparol D BinYo Jundang via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Argentina.gob.ar. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.